“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
Peer-Spectives
English - April 16, 2024 16:44 - 9 minutes - 12.8 MBScience Education obr oncology cancer healthcare medical obroncology peerspectives robertfiglin Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: “Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
Next Episode: Oncologist Shortage “Has Gotten to the Crisis Level”
The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, about the potential of moving these new drugs into the frontline setting and other questions related to BTK inhibitor resistance.
Dr. Woyach reported various financial relationships.
Dr. Figlin reported various financial relationships.